The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | BTK degradation shows promise in heavily pretreated CLL
Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses emerging data from the DAYBREAK CLL-201 trial (NCT07221500) on BTK degraders in heavily pretreated chronic lymphocytic leukemia (CLL). She highlights encouraging responses and manageable toxicity with bexobrutideg, including in patients previously exposed or refractory to both BTK and BCL2 inhibitors, and considers the potential of BTK degradation to address an important unmet need in CLL. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
